Tumoral platinum concentrations in patients treated with repeated low-dose cisplatin as a radiosensitizer

作者: Jean-Léon Lagrange , Pierre-Yves Bondiau , Eric Tessier , Pierre Chauvel , Nicole Renée

DOI: 10.1002/(SICI)1097-0215(19961115)68:4<452::AID-IJC9>3.0.CO;2-#

关键词:

摘要: The aim of the present study was to check whether platinum (Pt) concentrations achieved in tumors with a daily low-dose schedule were close those promoting radiosensitization. Fifteen previously untreated patients histologically proven advanced uterine cervix studied. They received irradiation 30 min after short infusion 5 mg cisplatin for consecutive days every week. A biopsy taken from accessible tumor mass, 4 6 hr injection. Blood samples obtained once week, just before injection (H0) and (H30). Quantificative analysis Pt performed by atomic absorption spectrophotometry. Plasma tumoral exhibited marked intersubject variability. median concentration 1,710 mg/g. Median total ultrafiltrable plasma at H0 H30 231 360 ng/ml, 7 90 ng/ml respectively. Tumoral significantly increased during course treatment. Present data show that this CDDP are range shown promote radiosensitization (2,000 ng/g). These results suggest regimen might be started higher doses order reach earlier radiosensitizing concentrations.

参考文章(24)
E. B. Douple, R. C. Richmond, Platinum complexes as radiosensitizers of hypoxic mammalian cells. The British journal of cancer. Supplement. ,vol. 3, pp. 98- 102 ,(1978)
Alain Gouyette, Annie Apchin, Maria Foka, Jean-Marie Richard, Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients European Journal of Cancer and Clinical Oncology. ,vol. 22, pp. 257- 263 ,(1986) , 10.1016/0277-5379(86)90389-5
Rudolf Schierl, Bettina Rohrer, J�rg Hohnloser, Long-term platinum excretion in patients treated with cisplatin. Cancer Chemotherapy and Pharmacology. ,vol. 36, pp. 75- 78 ,(1995) , 10.1007/BF00685736
JD Holding, WE Lindup, DA Bowdler, MZ Siodlak, PM Stell, Disposition and tumour concentrations of platinum in hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and neck British Journal of Clinical Pharmacology. ,vol. 32, pp. 173- 179 ,(1991) , 10.1111/J.1365-2125.1991.TB03878.X
DJ Stewart, JM Molepo, RM Green, VAJ Montpetit, H Hugenholtz, A Lamothe, NZ Mikhael, MD Redmond, M Gadia, R Goel, Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin British Journal of Cancer. ,vol. 71, pp. 598- 604 ,(1995) , 10.1038/BJC.1995.116
Gerrit Los, Frank A. Blommaert, Racine Barton, Dennis D. Heath, Leo den Engelse, Catherine Hanchett, Daniel Vicario, Robert Weisman, K. Thomas Robbins, Stephen B. Howell, Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation. Cancer Chemotherapy and Pharmacology. ,vol. 37, pp. 150- 154 ,(1995) , 10.1007/BF00685642
V. Troger, E. Francois, M. Frenay, M. Namer, G. Milano, Analysis of tissue platinum distribution in patients with cancer of the oesophagus European Journal of Cancer and Clinical Oncology. ,vol. 27, pp. 256- 259 ,(1991) , 10.1016/0277-5379(91)90510-K
J.L. Lagrange, J.L. Fischel, S. Galliani, P. Formento, T. Guillot, M. Bardon, G. Milano, Importance of the irradiation timing within a chemoradiotherapy sequence including cisplatin and 5-FU-folinic acid. Experimental results European Journal of Cancer. ,vol. 29, pp. 1531- 1535 ,(1993) , 10.1016/0959-8049(93)90289-R
B. Hecquet, P. Vennin, C. Fournier, J.L. Lefebvre, A. Caty, J. Bonneterre, L. Adenis, A. Demaille, Platinum concentration in human tumors of head and neck, uterine cervix, and breast following treatment with cisplatin. Cancer Chemotherapy and Pharmacology. ,vol. 15, pp. 310- 312 ,(1985) , 10.1007/BF00263908